Fulgent Genetics (NASDAQ:FLGT) vs. Biotricity (OTCMKTS:BTCY) Financial Survey

Biotricity (OTCMKTS:BTCY) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Biotricity and Fulgent Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-30.02%	N/A	-75.50%
Fulgent Genetics	-13.62%	-2.55%	-2.36%

Earnings & Valuation

This table compares Biotricity and Fulgent Genetics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$13.79 million	0.91	-$8.42 million	($0.17)	-2.65
Fulgent Genetics	$283.47 million	3.09	-$42.71 million	($1.39)	-20.36

Biotricity has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Biotricity has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Biotricity and Fulgent Genetics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	0	0	0	0.00
Fulgent Genetics	1	1	2	0	2.25

Fulgent Genetics has a consensus price target of $32.00, suggesting a potential upside of 13.07%. Given Fulgent Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Biotricity.

Institutional & Insider Ownership

3.9% of Biotricity shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 10.1% of Biotricity shares are held by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Fulgent Genetics beats Biotricity on 9 of the 14 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.